Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10498MR)

This product GTTS-WQ10498MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Osteoarthritis (OA), Migraine, Cluster headache (CH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10498MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7388MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ5773MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ7930MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ5158MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ10521MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ2997MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ9833MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ7853MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-1223249
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.